534 related articles for article (PubMed ID: 12657354)
21. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
[TBL] [Abstract][Full Text] [Related]
22. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
[TBL] [Abstract][Full Text] [Related]
23. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis.
Klus GT; Nakamura J; Li JS; Ling YZ; Son C; Kemppainen JA; Wilson EM; Brodie AM
Cancer Res; 1996 Nov; 56(21):4956-64. PubMed ID: 8895750
[TBL] [Abstract][Full Text] [Related]
24. Baicalin alleviates benign prostate hyperplasia through androgen-dependent apoptosis.
Jin BR; An HJ
Aging (Albany NY); 2020 Feb; 12(3):2142-2155. PubMed ID: 32018227
[TBL] [Abstract][Full Text] [Related]
25. Androgen-induced regrowth in the castrated rat ventral prostate: role of 5alpha-reductase.
Wright AS; Douglas RC; Thomas LN; Lazier CB; Rittmaster RS
Endocrinology; 1999 Oct; 140(10):4509-15. PubMed ID: 10499505
[TBL] [Abstract][Full Text] [Related]
26. Naftopidil enantiomers suppress androgen accumulation and induce cell apoptosis via the UDP-glucuronosyltransferase 2B15 in benign prostate hyperplasia.
Zhan H; Zhang S; Li L; Chen Z; Cai Y; Huang J; Wu D; Huang B; Wu B; Liu X
J Steroid Biochem Mol Biol; 2022 Jul; 221():106117. PubMed ID: 35504423
[TBL] [Abstract][Full Text] [Related]
27. Changes in the metabolism of dihydrotestosterone in the hyperplastic human prostate.
Isaacs JT; Brendler CB; Walsh PC
J Clin Endocrinol Metab; 1983 Jan; 56(1):139-46. PubMed ID: 6183287
[TBL] [Abstract][Full Text] [Related]
28. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
Isaacs JT; Coffey DS
Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma.
Mendoza P; Sánchez C; Contreras HR; Vergara J; Acevedo C; Cabezas J; Huidobro C; Noé G; Castellón EA
Int J Androl; 2009 Dec; 32(6):607-15. PubMed ID: 18637152
[TBL] [Abstract][Full Text] [Related]
30. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
[TBL] [Abstract][Full Text] [Related]
31. The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity.
Imperato-McGinley J; Gautier T; Cai LQ; Yee B; Epstein J; Pochi P
J Clin Endocrinol Metab; 1993 Feb; 76(2):524-8. PubMed ID: 8381804
[TBL] [Abstract][Full Text] [Related]
32. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
Traish AM
Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
[TBL] [Abstract][Full Text] [Related]
33. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
[TBL] [Abstract][Full Text] [Related]
34. Androgens and androgen-receptors in prostate tissue from patients with benign prostatic hyperplasia: effects of cyproterone acetate.
de Jong FH; Reuvers PJ; Bolt-de Vries J; Mulder E; Blom JH; Schroeder FH
J Steroid Biochem Mol Biol; 1992 Mar; 42(1):49-55. PubMed ID: 1373073
[TBL] [Abstract][Full Text] [Related]
35. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
Zhang Y; Ye L; Ding Q; Fang Z; Yao M; Shi D
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):545-7. PubMed ID: 11832106
[TBL] [Abstract][Full Text] [Related]
36. Effects of steroids on oxytocin secretion by the human prostate in vitro.
Assinder SJ; Nicholson HD
Int J Androl; 2004 Feb; 27(1):12-8. PubMed ID: 14718041
[TBL] [Abstract][Full Text] [Related]
37. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms--action of two new agents.
Kumar R; Verma V; Sarswat A; Maikhuri JP; Jain A; Jain RK; Sharma VL; Dalela D; Gupta G
Invest New Drugs; 2012 Apr; 30(2):582-93. PubMed ID: 21181231
[TBL] [Abstract][Full Text] [Related]
38. Development of a new gas chromatography-mass spectrometry (GC-MS) methodology for the evaluation of 5α-reductase activity.
Amaral C; Cunha SC; Fernandes JO; Tavares da Silva E; Roleira FM; Teixeira N; Correia-da-Silva G
Talanta; 2013 Mar; 107():154-61. PubMed ID: 23598206
[TBL] [Abstract][Full Text] [Related]
39. Effect of megestrol acetate (Megace) on steroid metabolism and steroid-protein binding in the human prostate.
Geller J; Albert J; Geller S; Lopez D; Cantor T; Yen S
J Clin Endocrinol Metab; 1976 Nov; 43(5):1000-8. PubMed ID: 62759
[TBL] [Abstract][Full Text] [Related]
40. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
